Lead Product(s): Egrifta
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2020
Theratechnologies Inc. signed of long-term agreements with the MGH towards the development of tesamorelin for the treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.